NP-G2-044: Clinical Trials

2 trials of NP-G2-044, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Active not recruiting 1
Phase 31Active not recruiting 1

Follow NP-G2-044: new trials by email Literature Review of NP-G2-044 trials Research Report on NP-G2-044

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NP-G2-044, PLD - Platinum-resistant Ovarian Cancer
Phase 2 / Phase 3Active not recruitingNovita Pharmaceuticals, Inc.3802025-12-292026-03-09
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
NP-G2-044 - Breast Cancer, Pancreas Cancer
Phase 1CompletedNovita Pharmaceuticals, Inc.232017-12-212025-07-20

Conditions studied

Ovarian Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Colonic Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Novita Pharmaceuticals, Inc. (2)

Countries

United States (2)

Top investigators

Jillian Zhang, Ph.D. (1)  ·  Jillian Zhang, PhD (1)  ·  Lisa Barroilhet, MD (1)

Results publications

PMID 33188449, PMID 41707378